Replies to post #2291 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

So do we know for certain that the MOA of ENTAs drug identical?

ENTA's EDP-235 and PFE's Paxlovid both inhibit the Sars-Cov-2 3CL protease by interfering with the active site of that protease. ENTA is suing PFE for violation of their patent.

[DewDiligence]

Elaborating on #msg-169566734, the MoA of EDP-235 could not be simpler: EDP-235 stops SARS-CoV-2 viral replication. If the next EDP-235 trial (either phase-2 or phase2/3—see #msg-169566784) has a well-chosen endpoint and an appropriate patient pool (e.g. rate of hospitalization, compared to placebo, in high-risk patients), EDP-235 is a big favorite to show meaningful efficacy. To put it another way, ENTA (and a potential partner) would have to screw up royally for EDP-235 to not be successful in the next trial.

p.s. The above may not be entirely clear to investors who are unfamiliar with clinical development of antiviral drugs. This is probably why ENTA’s recent 40% pop occurred over the course of a week rather than in a single day.